Logo image of TWST

TWIST BIOSCIENCE CORP (TWST) Stock Fundamental Analysis

USA - NASDAQ:TWST - US90184D1000 - Common Stock

28.16 USD
-2.59 (-8.42%)
Last: 10/17/2025, 8:00:01 PM
28.3 USD
+0.14 (+0.5%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TWST. TWST was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TWST as it has an excellent financial health rating, but there are worries on the profitability. TWST is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year TWST has reported negative net income.
TWST had a negative operating cash flow in the past year.
In the past 5 years TWST always reported negative net income.
In the past 5 years TWST always reported negative operating cash flow.
TWST Yearly Net Income VS EBIT VS OCF VS FCFTWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

TWST has a better Return On Assets (-13.24%) than 82.24% of its industry peers.
TWST's Return On Equity of -17.81% is amongst the best of the industry. TWST outperforms 85.98% of its industry peers.
Industry RankSector Rank
ROA -13.24%
ROE -17.81%
ROIC N/A
ROA(3y)-27.66%
ROA(5y)-27.95%
ROE(3y)-34.86%
ROE(5y)-34.47%
ROIC(3y)N/A
ROIC(5y)N/A
TWST Yearly ROA, ROE, ROICTWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

The Gross Margin of TWST (49.24%) is better than 75.70% of its industry peers.
In the last couple of years the Gross Margin of TWST has grown nicely.
TWST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y27.06%
TWST Yearly Profit, Operating, Gross MarginsTWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TWST has been increased compared to 1 year ago.
The number of shares outstanding for TWST has been increased compared to 5 years ago.
There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TWST Yearly Shares OutstandingTWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TWST Yearly Total Debt VS Total AssetsTWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

TWST has an Altman-Z score of 3.66. This indicates that TWST is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TWST (3.66) is better than 71.40% of its industry peers.
TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.66
ROIC/WACCN/A
WACC9.35%
TWST Yearly LT Debt VS Equity VS FCFTWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

TWST has a Current Ratio of 3.90. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
TWST's Current ratio of 3.90 is in line compared to the rest of the industry. TWST outperforms 45.05% of its industry peers.
TWST has a Quick Ratio of 3.60. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
TWST has a Quick ratio of 3.60. This is comparable to the rest of the industry: TWST outperforms 44.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.9
Quick Ratio 3.6
TWST Yearly Current Assets VS Current LiabilitesTWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

TWST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.10%, which is quite impressive.
TWST shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.72%.
Measured over the past years, TWST shows a very strong growth in Revenue. The Revenue has been growing by 41.90% on average per year.
EPS 1Y (TTM)41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.03%
Revenue 1Y (TTM)22.72%
Revenue growth 3Y33.24%
Revenue growth 5Y41.9%
Sales Q2Q%17.91%

3.2 Future

Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
The Revenue is expected to grow by 16.70% on average over the next years. This is quite good.
EPS Next Y58.85%
EPS Next 2Y25.95%
EPS Next 3Y17.91%
EPS Next 5Y13.7%
Revenue Next Year20.56%
Revenue Next 2Y19.02%
Revenue Next 3Y18.35%
Revenue Next 5Y16.7%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TWST Yearly Revenue VS EstimatesTWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
TWST Yearly EPS VS EstimatesTWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TWST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TWST Price Earnings VS Forward Price EarningsTWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TWST Per share dataTWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as TWST's earnings are expected to grow with 17.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.95%
EPS Next 3Y17.91%

More info and screens

0

5. Dividend

5.1 Amount

TWST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TWIST BIOSCIENCE CORP

NASDAQ:TWST (10/17/2025, 8:00:01 PM)

After market: 28.3 +0.14 (+0.5%)

28.16

-2.59 (-8.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-17 2025-11-17/amc
Inst Owners115.89%
Inst Owner Change0.02%
Ins Owners1.33%
Ins Owner Change-2.59%
Market Cap1.70B
Analysts83.75
Price Target45.58 (61.86%)
Short Float %21.65%
Short Ratio7.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.57%
Min EPS beat(2)-12.39%
Max EPS beat(2)17.53%
EPS beat(4)3
Avg EPS beat(4)10.46%
Min EPS beat(4)-12.39%
Max EPS beat(4)18.55%
EPS beat(8)6
Avg EPS beat(8)-2.76%
EPS beat(12)10
Avg EPS beat(12)7.02%
EPS beat(16)13
Avg EPS beat(16)8.07%
Revenue beat(2)0
Avg Revenue beat(2)-1.31%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-1.51%
Max Revenue beat(4)1.03%
Revenue beat(8)6
Avg Revenue beat(8)1.66%
Revenue beat(12)8
Avg Revenue beat(12)1.45%
Revenue beat(16)12
Avg Revenue beat(16)2.28%
PT rev (1m)0%
PT rev (3m)-12.75%
EPS NQ rev (1m)-1.07%
EPS NQ rev (3m)3.11%
EPS NY rev (1m)-5.69%
EPS NY rev (3m)33.24%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.69
P/FCF N/A
P/OCF N/A
P/B 3.55
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS6
BVpS7.92
TBVpS6.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.24%
ROE -17.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.24%
FCFM N/A
ROA(3y)-27.66%
ROA(5y)-27.95%
ROE(3y)-34.86%
ROE(5y)-34.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y27.06%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.92%
Cap/Sales 4.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.9
Quick Ratio 3.6
Altman-Z 3.66
F-Score5
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)242.63%
Cap/Depr(5y)230.64%
Cap/Sales(3y)21%
Cap/Sales(5y)18.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.03%
EPS Next Y58.85%
EPS Next 2Y25.95%
EPS Next 3Y17.91%
EPS Next 5Y13.7%
Revenue 1Y (TTM)22.72%
Revenue growth 3Y33.24%
Revenue growth 5Y41.9%
Sales Q2Q%17.91%
Revenue Next Year20.56%
Revenue Next 2Y19.02%
Revenue Next 3Y18.35%
Revenue Next 5Y16.7%
EBIT growth 1Y23.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.85%
EBIT Next 3Y23.42%
EBIT Next 5Y18.32%
FCF growth 1Y58.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.44%
OCF growth 3YN/A
OCF growth 5YN/A